Technical Analysis for NTBL - Notable Labs, Ltd.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 1,2,3 Pullback Bullish | Bullish Swing Setup | -2.41% | |
| Calm After Storm | Range Contraction | -2.41% | |
| Doji - Bullish? | Reversal | -2.41% | |
| Wide Bands | Range Expansion | -2.41% | |
| Down 3 Days in a Row | Weakness | -2.41% | |
| Down 4 Days in a Row | Weakness | -2.41% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | -4.18% | |
| Calm After Storm | Range Contraction | -4.18% | |
| Earnings Movers | Other | -4.18% | |
| Wide Bands | Range Expansion | -4.18% |
| Alert | Time |
|---|---|
| 20 DMA Support | 7 minutes ago |
| 60 Minute Opening Range Breakdown | 7 minutes ago |
| Down 3% | 7 minutes ago |
| Down 2 % | 7 minutes ago |
| Fell Below Previous Day's Low | about 3 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/13/2024
Notable Labs, Ltd. Description
Notable Labs, Ltd., a clinical-stage platform therapeutics company, engages in developing predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient is likely to respond to that specific therapeutic. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and thus fast-track clinical development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor for acute myeloid leukemia (AML), pediatric leukemia, and myelodysplastic syndromes indications; and Fosciclopirox, a pro-drug of ciclopirox for AML. Notable Labs, Ltd. is headquartered in Foster City, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Cancer Treatment Acute Myeloid Leukemia Orphan Drug Protein Kinase Inhibitor Myelodysplastic Syndrome Chronic Myeloid Leukemia Kinase 1 Lintuzumab
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 11.2 |
| 52 Week Low | 0.833 |
| Average Volume | 464,904 |
| 200-Day Moving Average | 3.62 |
| 50-Day Moving Average | 1.33 |
| 20-Day Moving Average | 1.04 |
| 10-Day Moving Average | 1.12 |
| Average True Range | 0.18 |
| RSI (14) | 46.24 |
| ADX | 31.7 |
| +DI | 29.78 |
| -DI | 16.95 |
| Chandelier Exit (Long, 3 ATRs) | 1.30 |
| Chandelier Exit (Short, 3 ATRs) | 1.37 |
| Upper Bollinger Bands | 1.32 |
| Lower Bollinger Band | 0.76 |
| Percent B (%b) | 0.57 |
| BandWidth | 53.58 |
| MACD Line | -0.03 |
| MACD Signal Line | -0.06 |
| MACD Histogram | 0.0347 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.27 | ||||
| Resistance 3 (R3) | 1.29 | 1.24 | 1.24 | ||
| Resistance 2 (R2) | 1.24 | 1.19 | 1.23 | 1.23 | |
| Resistance 1 (R1) | 1.16 | 1.16 | 1.14 | 1.14 | 1.22 |
| Pivot Point | 1.11 | 1.11 | 1.10 | 1.10 | 1.11 |
| Support 1 (S1) | 1.03 | 1.06 | 1.01 | 1.02 | 0.94 |
| Support 2 (S2) | 0.98 | 1.03 | 0.97 | 0.93 | |
| Support 3 (S3) | 0.90 | 0.98 | 0.92 | ||
| Support 4 (S4) | 0.89 |
